Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer
Completed
Conditions studied: Breast Cancer, Osteoporosis
In brief
RATIONALE: Tamoxifen may be able to increase bone density and decrease cholesterol in women who are undergoing chemotherapy for breast cancer. PURPOSE: Clinical trial to study the effectiveness of tamoxifen in preventing bone loss and heart disease caused by chemotherapy treatment in premenopausal women who have stage I or stage II breast cancer.
Key facts
- Study ID
- NCT00005605
- Run by
- Northwestern University
- People needed
- 79
- Starts
- 2000-02-01
- Expected to finish
- 2005-10-01
- Last updated by the study team
- 2011-02-21
Who can join
Age: 35 and older, up to 50. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.